Dr. Setareh Shamsili became the new Chief Medical Officer at Selvita. This is another personnel change in the Polish biotechnology company. We have written about the previous ones here and here.
From AxImmune to Selvita
Dr. Shamsili has more than 20 years of experience in clinical oncology and drug development. Prior to joining Selvity, she served as Medical Director at AxImmune, the US immunooncology company. Previously, Dr. Shamsili was an external consultant to American and European biotechnology companies, specialising in the development of immunooncology projects. She specialised in the development of programs at different stages, from small molecules to antibodies and cancer vaccines.
In her career, she also worked for Merus NV, where she introduced two potential candidates to clinical trials for acute myeloid leukemia and solid tumors.
Valuable experience in the US
Selvita counts on the strategic support of Dr. Shamsili in the process of developing a portfolio of its research products. Particularly important is the experience of the new medical director in the US market. Selvita wants to conduct the first phase of SEL120 clinical trials there. SEL120 is a selective CDK8 kinase inhibitor that can be used to treat acute myeloid leukemia and myelodysplastic syndromes.
Selvita selects candidates for clinical trials from its own research and development platform. This allows to expand the portfolio of projects which are being developed. It also allows for parallel work on several innovative, first or best in class particles at the same time.
In March Selvita announced a plan to split into two companies, one of which will focus on the development of its own projects in the area of small molecules with therapeutic potential in oncology. It will be finalised in Q4 2019.